UKIBCS 2020

UKIBCS 2020 Evaluation

Question Title

* 1. How would you rate your overall conference experience

Excellent

Very good

Good

Average

Poor

Question Title

* 2. Please rate the conference in terms of knowledge gained

Excellent

Very good

Good

Average

Poor

Question Title

* 3. Do you think the programme was well balanced?

Yes

If no, please specify:

Question Title

* 4. Please rate the conference sessions you attended

	Excellent	Very good	Good	Average	Poor
Highlights	Highlights Excellent	Highlights Very good	Highlights Good	Highlights Average	Highlights Poor
Keynote lecture: Philip Poortmans	Keynote lecture: Philip Poortmans Excellent	Keynote lecture: Philip Poortmans Very good	Keynote lecture: Philip Poortmans Good	Keynote lecture: Philip Poortmans Average	Keynote lecture: Philip Poortmans Poor
Demystifying partial breast irradiation	Demystifying partial breast irradiation Excellent	Demystifying partial breast irradiation Very good	Demystifying partial breast irradiation Good	Demystifying partial breast irradiation Average	Demystifying partial breast irradiation Poor
Big data in breast cancer	Big data in breast cancer Excellent	Big data in breast cancer Very good	Big data in breast cancer Good	Big data in breast cancer Average	Big data in breast cancer Poor
Why can't we kill ER+ breast cancer?	Why can't we kill ER+ breast cancer? Excellent	Why can't we kill ER+ breast cancer? Very good	Why can't we kill ER+ breast cancer? Good	Why can't we kill ER+ breast cancer? Average	Why can't we kill ER+ breast cancer? Poor
Managing the side effects of endocrine therapy	Managing the side effects of endocrine therapy Excellent	Managing the side effects of endocrine therapy Very good	Managing the side effects of endocrine therapy Good	Managing the side effects of endocrine therapy Average	Managing the side effects of endocrine therapy Poor
Sponsored symposium: Exact Sciences	Sponsored symposium: Exact Sciences Excellent	Sponsored symposium: Exact Sciences Very good	Sponsored symposium: Exact Sciences Good	Sponsored symposium: Exact Sciences Average	Sponsored symposium: Exact Sciences Poor
Sponsored symposium: Roche	Sponsored symposium: Roche Excellent	Sponsored symposium: Roche Very good	Sponsored symposium: Roche Good	Sponsored symposium: Roche Average	Sponsored symposium: Roche Poor
Sponsored symposium: Pfizer	Sponsored symposium: Pfizer Excellent	Sponsored symposium: Pfizer Very good	Sponsored symposium: Pfizer Good	Sponsored symposium: Pfizer Average	Sponsored symposium: Pfizer Poor
Keynote Lecture: Matthew Ellis	Keynote Lecture: Matthew Ellis Excellent	Keynote Lecture: Matthew Ellis Very good	Keynote Lecture: Matthew Ellis Good	Keynote Lecture: Matthew Ellis Average	Keynote Lecture: Matthew Ellis Poor
DCIS - Risk estimates and management	DCIS - Risk estimates and management Excellent	DCIS - Risk estimates and management Very good	DCIS - Risk estimates and management Good	DCIS - Risk estimates and management Average	DCIS - Risk estimates and management Poor
Special issues in managing metastatic disease	Special issues in managing metastatic disease Excellent	Special issues in managing metastatic disease Very good	Special issues in managing metastatic disease Good	Special issues in managing metastatic disease Average	Special issues in managing metastatic disease Poor
Phenotypic and genotypic heterogenity	Phenotypic and genotypic heterogenity Excellent	Phenotypic and genotypic heterogenity Very good	Phenotypic and genotypic heterogenity Good	Phenotypic and genotypic heterogenity Average	Phenotypic and genotypic heterogenity Poor
Free Communications 1	Free Communications 1 Excellent	Free Communications 1 Very good	Free Communications 1 Good	Free Communications 1 Average	Free Communications 1 Poor
Managing the axilla	Managing the axilla Excellent	Managing the axilla Very good	Managing the axilla Good	Managing the axilla Average	Managing the axilla Poor
Late recurrence in ER+ disease	Late recurrence in ER+ disease Excellent	Late recurrence in ER+ disease Very good	Late recurrence in ER+ disease Good	Late recurrence in ER+ disease Average	Late recurrence in ER+ disease Poor
Improving breast cancer outcomes by modifying lifestyle	Improving breast cancer outcomes by modifying lifestyle Excellent	Improving breast cancer outcomes by modifying lifestyle Very good	Improving breast cancer outcomes by modifying lifestyle Good	Improving breast cancer outcomes by modifying lifestyle Average	Improving breast cancer outcomes by modifying lifestyle Poor
Novel clinical trial design	Novel clinical trial design Excellent	Novel clinical trial design Very good	Novel clinical trial design Good	Novel clinical trial design Average	Novel clinical trial design Poor
Keynote Lecture: Eric Winer	Keynote Lecture: Eric Winer Excellent	Keynote Lecture: Eric Winer Very good	Keynote Lecture: Eric Winer Good	Keynote Lecture: Eric Winer Average	Keynote Lecture: Eric Winer Poor
Keynote Lecture: Martine Piccart	Keynote Lecture: Martine Piccart Excellent	Keynote Lecture: Martine Piccart Very good	Keynote Lecture: Martine Piccart Good	Keynote Lecture: Martine Piccart Average	Keynote Lecture: Martine Piccart Poor
Modernising breast MDT meetings	Modernising breast MDT meetings Excellent	Modernising breast MDT meetings Very good	Modernising breast MDT meetings Good	Modernising breast MDT meetings Average	Modernising breast MDT meetings Poor
Immune therapy	Immune therapy Excellent	Immune therapy Very good	Immune therapy Good	Immune therapy Average	Immune therapy Poor
Modelling breast cancer - moving closer to the clinic	Modelling breast cancer - moving closer to the clinic Excellent	Modelling breast cancer - moving closer to the clinic Very good	Modelling breast cancer - moving closer to the clinic Good	Modelling breast cancer - moving closer to the clinic Average	Modelling breast cancer - moving closer to the clinic Poor
Trials in progress	Trials in progress Excellent	Trials in progress Very good	Trials in progress Good	Trials in progress Average	Trials in progress Poor
Keynote Lecture: Judy Garber	Keynote Lecture: Judy Garber Excellent	Keynote Lecture: Judy Garber Very good	Keynote Lecture: Judy Garber Good	Keynote Lecture: Judy Garber Average	Keynote Lecture: Judy Garber Poor
Breast cancer risk and prevention	Breast cancer risk and prevention Excellent	Breast cancer risk and prevention Very good	Breast cancer risk and prevention Good	Breast cancer risk and prevention Average	Breast cancer risk and prevention Poor
Prognostic and predictive profiling	Prognostic and predictive profiling Excellent	Prognostic and predictive profiling Very good	Prognostic and predictive profiling Good	Prognostic and predictive profiling Average	Prognostic and predictive profiling Poor
Special issues in managing young patients	Special issues in managing young patients Excellent	Special issues in managing young patients Very good	Special issues in managing young patients Good	Special issues in managing young patients Average	Special issues in managing young patients Poor
Free Communications II	Free Communications II Excellent	Free Communications II Very good	Free Communications II Good	Free Communications II Average	Free Communications II Poor
Sponsored symposium: Nanostring	Sponsored symposium: Nanostring Excellent	Sponsored symposium: Nanostring Very good	Sponsored symposium: Nanostring Good	Sponsored symposium: Nanostring Average	Sponsored symposium: Nanostring Poor
Sponsored symposium: Lilly	Sponsored symposium: Lilly Excellent	Sponsored symposium: Lilly Very good	Sponsored symposium: Lilly Good	Sponsored symposium: Lilly Average	Sponsored symposium: Lilly Poor
Sponsored symposium: Daiichi Sankyo	Sponsored symposium: Daiichi Sankyo Excellent	Sponsored symposium: Daiichi Sankyo Very good	Sponsored symposium: Daiichi Sankyo Good	Sponsored symposium: Daiichi Sankyo Average	Sponsored symposium: Daiichi Sankyo Poor
Keynote Lecture: Monica Morrow	Keynote Lecture: Monica Morrow Excellent	Keynote Lecture: Monica Morrow Very good	Keynote Lecture: Monica Morrow Good	Keynote Lecture: Monica Morrow Average	Keynote Lecture: Monica Morrow Poor
Minimising mastectomy	Minimising mastectomy Excellent	Minimising mastectomy Very good	Minimising mastectomy Good	Minimising mastectomy Average	Minimising mastectomy Poor
Special issues for elderly patients	Special issues for elderly patients Excellent	Special issues for elderly patients Very good	Special issues for elderly patients Good	Special issues for elderly patients Average	Special issues for elderly patients Poor
Translating new therapeutic opportunities	Translating new therapeutic opportunities Excellent	Translating new therapeutic opportunities Very good	Translating new therapeutic opportunities Good	Translating new therapeutic opportunities Average	Translating new therapeutic opportunities Poor
Young clinical leaders	Young clinical leaders Excellent	Young clinical leaders Very good	Young clinical leaders Good	Young clinical leaders Average	Young clinical leaders Poor
Keynote Lecture: David Cameron	Keynote Lecture: David Cameron Excellent	Keynote Lecture: David Cameron Very good	Keynote Lecture: David Cameron Good	Keynote Lecture: David Cameron Average	Keynote Lecture: David Cameron Poor

Other (please specify)

Question Title

* 5. How would you rate your experience of the poster viewing?

Excellent

Very good

Good

Average

Poor

Please add any comments here:

Question Title

* 6. Do you think it is useful for patient advocates to attend and participate in the UKIBCS?

Yes

Question Title

* 7. Please rate these specific aspects of the conference

	Excellent	Very good	Good	Average	Poor
Venue	Venue Excellent	Venue Very good	Venue Good	Venue Average	Venue Poor
Location/Access	Location/Access Excellent	Location/Access Very good	Location/Access Good	Location/Access Average	Location/Access Poor
Catering	Catering Excellent	Catering Very good	Catering Good	Catering Average	Catering Poor
Accommodation	Accommodation Excellent	Accommodation Very good	Accommodation Good	Accommodation Average	Accommodation Poor

UKIBCS 2020

UKIBCS 2020 Evaluation

Question Title

* 1. How would you rate your overall conference experience

Question Title

* 2. Please rate the conference in terms of knowledge gained

Question Title

* 3. Do you think the programme was well balanced?

Question Title

* 4. Please rate the conference sessions you attended

Question Title

* 5. How would you rate your experience of the poster viewing?

Question Title

* 6. Do you think it is useful for patient advocates to attend and participate in the UKIBCS?

Question Title

* 7. Please rate these specific aspects of the conference

Question Title

* 8. What topics would you like to suggest for future meetings?

Question Title

* 9. Do you have any other comments on the meeting?